Nektar Therapeutics
NKTRNKTR · Stock Price
Historical price data
Overview
Nektar Therapeutics is dedicated to developing transformative immunomodulatory therapies that restore immune homeostasis in autoimmune and inflammatory diseases. The company's core strategy leverages a deep understanding of immunology to engineer first-in-class agonists targeting upstream regulatory nodes, specifically the IL-2 and TNFR2 pathways, to expand regulatory T cells. With its lead candidate, rezpegaldesleukin, advancing in multiple Phase 2b trials, a seasoned leadership team, and a proven track record of strategic partnerships, Nektar aims to shift treatment paradigms from broad immunosuppression to targeted immune recalibration.
Technology Platform
Proprietary platform engineering agonists that selectively target the IL-2 and TNFR2 pathways to expand and enhance the function of regulatory T cells (Tregs), aiming to restore immune homeostasis.
Pipeline
34| Drug | Indication | Stage | Watch |
|---|---|---|---|
| NKTR-102 + Eribulin + Ixabepilone + Vinorelbine + Gemcitabin... | Metastasis | Phase 3 | |
| NKTR-181 BID tablets + Placebo to match NKTR-181 BID tablets | Low Back Pain | Phase 3 | |
| NKTR-102 + Treatment of Physician's Choice (TPC) | Locally Recurrent Breast Cancer | Phase 3 | |
| NKTR-181 BID tablets | Low Back Pain | Phase 3 | |
| NKTR-255 at 1.5 µg/kg + NKTR-255 at 3.0 μg/kg + NKTR-255 at ... | Non-Hodgkin Lymphoma | Phase 2/3 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Nektar competes with large-cap pharma's entrenched anti-cytokine biologics and JAK inhibitors, and with other biotechs developing Treg-targeting therapies. Its differentiation lies in the clinical-stage advancement of its selective IL-2 agonist and its complementary TNFR2 agonist platform.
Company Timeline
Initial Public Offering
PIPE: $200.0M
Debt: $150.0M